Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.
about
Multiple sodium channel isoforms mediate the pathological effects of Pacific ciguatoxin-1.Voltage-gated Na+ currents in human dorsal root ganglion neurons.Using automated patch clamp electrophysiology platforms in pain-related ion channel research: insights from industry and academia.Methods Used to Evaluate Pain Behaviors in Rodents.Lengths of the C-Terminus and Interconnecting Loops Impact Stability of Spider-Derived Gating Modifier Toxins.The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Nav1.7.Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.Overlooked Short Toxin-Like Proteins: A Shortcut to Drug Design.A novel human pain insensitivity disorder caused by a point mutation in ZFHX2.Sodium channels and pain: from toxins to therapies.Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V.Analgesia linked to Nav1.7 loss of function requires µ- and δ-opioid receptorsPrediction of disulfide dihedral angles using chemical shiftsDiscovery of a Novel Na1.7 Inhibitor From Venom With Potent Analgesic EfficacyThe Na1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons
P2860
Q30839530-7989E063-E0DB-4CEA-86B8-CF545FE4D2F1Q33694104-04D0BD8F-2276-4E83-B753-B14E38DA5A43Q39378653-07CC1B32-BA15-4856-92E6-40EA15DC187FQ41440352-D6294EE8-6C6F-4065-BC7A-830AD8C6B4F1Q41569702-92ACEA33-5A90-4A8C-9DCD-DED76CF183A9Q41665872-13C1F315-91C5-4B7C-BC08-D6E2089035A6Q43075742-44875988-7DE2-4660-8BE9-4DE32F2C47FDQ45944104-6AE82A1F-6367-4DE7-A127-2025E607022BQ47909403-996D8EAB-F4BD-49C5-8AA3-61A7B1C6B698Q48337085-E2A7216E-5F52-4190-AAA3-B0459AE82E77Q55037976-53A9CDCE-BEB8-4CC8-9773-D821D203AD74Q57133342-927CE48A-BFB7-4990-A747-06E4C4CE02D8Q57496279-BE08748C-3FC0-487A-85E4-39EE3504E6DEQ58554174-A5A6C84F-A748-4EDF-A436-23D9CED7C7CCQ58764681-FB872B00-B228-48A0-A94C-A025B021B633
P2860
Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Pharmacological characterisati ...... ive spider venom peptide Pn3a.
@ast
Pharmacological characterisati ...... ive spider venom peptide Pn3a.
@en
type
label
Pharmacological characterisati ...... ive spider venom peptide Pn3a.
@ast
Pharmacological characterisati ...... ive spider venom peptide Pn3a.
@en
prefLabel
Pharmacological characterisati ...... ive spider venom peptide Pn3a.
@ast
Pharmacological characterisati ...... ive spider venom peptide Pn3a.
@en
P2093
P2860
P50
P356
P1433
P1476
Pharmacological characterisati ...... ive spider venom peptide Pn3a.
@en
P2093
David A Armstrong
John N Wood
Joshua S Wingerd
Macdonald J Christie
Michael S Minett
Nehan R Munasinghe
Pierre Escoubas
Rebecca F Bhola
Stephen G Waxman
Sulayman D Dib-Hajj
P2860
P2888
P356
10.1038/SREP40883
P407
P50
P577
2017-01-20T00:00:00Z
P6179
1053923205